An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Launched by NOVO NORDISK A/S · Jan 12, 2012
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This active surveillance program will monitor for any signal indicating a possible association between treatment with long-acting GLP-1 RAs and the development of MTC in the United States population. Given the very low incidence of MTC in the general population, the expected rate of exposure to long-acting GLP-1 RAs, the anticipated long latency of the potential outcome under study and the limited data on underlying risk factors for development of MTC other than RET proto-oncogene mutations, an active surveillance program is the most efficient means of identifying a possible association bet...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
- • At least 18 years or older.
- • There are no other inclusion or exclusion criteria.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Morgantown, West Virginia, United States
Patients applied
Trial Officials
Annette Stemhagen, DrPH, FISPE
Study Director
United BioSource, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials